Patents by Inventor Michael Xiang

Michael Xiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE
    Publication number: 20250214972
    Abstract: A five-membered-fused six-membered compound, a preparation method, a pharmaceutical composition, and the use. The penta-fused hexa-heterocyclic compound is a compound represented by formula (II) or (III). The compound has an inhibition or/and degradation effect on IRAK4.
    Type: Application
    Filed: March 21, 2025
    Publication date: July 3, 2025
    Inventors: Jason Shaoyun Xiang, Lei Wu, Rui Xu, Qiang Zhang, Gang Yang, Michael Xiang, Mixue Tong, Camille Xiang, Suyue Wang, Rui Yang
  • Five-membered-fused six-membered compound, preparation method, pharmaceutical composition and use
    Patent number: 12281098
    Abstract: A five-membered-fused six-membered compound, a preparation method, a pharmaceutical composition, and the use. The penta-fused hexa-heterocyclic compound is a compound represented by formula (II) or (III). The compound has an inhibition or/and degradation effect on IRAK4.
    Type: Grant
    Filed: April 11, 2024
    Date of Patent: April 22, 2025
    Assignee: HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.
    Inventors: Jason Shaoyun Xiang, Lei Wu, Rui Xu, Qiang Zhang, Gang Yang, Michael Xiang, Mixue Tong, Camille Xiang, Suyue Wang, Rui Yang
  • Five- and six-membered compound, and preparation method therefor and pharmaceutical composition and use thereof
    Patent number: 12195479
    Abstract: A five-membered-fused six-membered compound, and a preparation method therefor and a pharmaceutical composition and the use thereof. The five- and six-membered compound is a compound as shown in formula I, II or III. The compound has an inhibitory effect on FLT3 and/or IRAK4.
    Type: Grant
    Filed: December 19, 2023
    Date of Patent: January 14, 2025
    Assignee: HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.
    Inventors: Jason Shaoyun Xiang, Lei Wu, Rui Xu, Qiang Zhang, Gang Yang, Michael Xiang, Mixue Tong, Camille Xiang, Yuxin Liu, Suyue Wang, Rui Yang
  • FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE
    Publication number: 20240294502
    Abstract: A five-membered-fused six-membered compound, a preparation method, a pharmaceutical composition, and the use. The penta-fused hexa-heterocyclic compound is a compound represented by formula (II) or (III). The compound has an inhibition or/and degradation effect on IRAK4.
    Type: Application
    Filed: April 11, 2024
    Publication date: September 5, 2024
    Inventors: Jason Shaoyun XIANG, Lei WU, Rui XU, Qiang ZHANG, Gang YANG, Michael XIANG, Mixue TONG, Camille XIANG, Suyue WANG, Rui YANG
  • FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
    Publication number: 20240208993
    Abstract: A five-membered-fused six-membered compound, and a preparation method therefor and a pharmaceutical composition and the use thereof. The five- and six-membered compound is a compound as shown in formula I, II or III. The compound has an inhibitory effect on FLT3 and/or IRAK4.
    Type: Application
    Filed: December 19, 2023
    Publication date: June 27, 2024
    Inventors: Jason Shaoyun XIANG, Lei WU, Rui XU, Qiang ZHANG, Gang YANG, Michael XIANG, Mixue TONG, Camille XIANG, Yuxin LIU, Suyue WANG, Rui YANG
  • Methods of treating cancer with atovaquone-related compounds
    Patent number: 10130590
    Abstract: Described herein are, inter alia, methods for decreasing the growth of a cancer cell, the method comprising delivering to a target cancer cell a growth-inhibitory amount of an atovaquone-related compound, wherein, prior to the delivery, an increased level of activation of the mTOR pathway in the cancer compared to a control level of activation of the mTOR pathway has been found. Also provided are methods for determining the susceptibility of cancer to treatment with an atovaquone-related compound and for assessing the success of therapy with such a compound.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: November 20, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: David Frank, Michael Xiang
  • Methods of Treating Cancer with Atovaquone-Related Compounds
    Publication number: 20160296480
    Abstract: Described herein are, inter alia, methods for decreasing the growth of a cancer cell, the method comprising delivering to a target cancer cell a growth-inhibitory amount of an atovaquone-related compound, wherein, prior to the delivery, an increased level of activation of the mTOR pathway in the cancer compared to a control level of activation of the mTOR pathway has been found. Also provided are methods for determining the susceptibility of cancer to treatment with an atovaquone-related compound and for assessing the success of therapy with such a compound.
    Type: Application
    Filed: September 30, 2014
    Publication date: October 13, 2016
    Inventors: David Frank, Michael Xiang